Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 100 of 133 entries
View as:

A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06732323 Org: User:
Start: 09/30/25 End: 07/31/28 Due: 07/31/29

Study of QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated LDL Cholesterol

Phase: N/A Priority: Normal
NCT ID: NCT06750341 Org: User:
Start: 02/28/25 End: 09/30/26 Due: 09/30/27

Efficacy and Safety of QL1012 in Women for Assisted Reproductive Treatment

Phase: N/A Priority: Normal
NCT ID: NCT05149924 Org: User:
Start: 10/31/18 End: 10/17/19 Due: 10/17/20

Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance

Phase: N/A Priority: Normal
NCT ID: NCT03267654 Org: User:
Start: 10/12/17 End: 12/30/21 Due: 12/30/22

A Phase 2 Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19

Phase: N/A Priority: Normal
NCT ID: NCT05689203 Org: User:
Start: 12/30/22 End: 02/01/23 Due: 02/01/24

QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC

Phase: N/A Priority: Normal
NCT ID: NCT05799820 Org: User:
Start: 09/29/22 End: 09/30/25 Due: 09/30/26

A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients

Phase: N/A Priority: Normal
NCT ID: NCT06911827 Org: User:
Start: 04/30/25 End: 12/31/28 Due: 12/31/29

Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR

Phase: N/A Priority: Normal
NCT ID: NCT03381430 Org: User:
Start: 06/30/18 End: 12/31/25 Due: 12/31/26

A Study to Investigate the Safety, Efficacy and PK of Multiple Doses of QL-007 in Chronic Hepatitis B Patients in CHINA

Phase: N/A Priority: Normal
NCT ID: NCT03770624 Org: User:
Start: 10/16/18 End: 04/30/19 Due: 04/30/20

An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Entecavir or Tenofovir in Patients With Chronic Hepatitis b Who Have Received Nucleoside (Acid) Therapy

Phase: N/A Priority: Normal
NCT ID: NCT04157257 Org: User:
Start: 07/26/19 End: 10/31/22 Due: 10/31/23

Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06942767 Org: User:
Start: 06/30/25 End: 03/31/28 Due: 03/31/29

A Study of QLF32101 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT05703204 Org: User:
Start: 02/01/23 End: 12/21/24 Due: 12/21/25

Compare the Efficacy and Safety of QL0605 Injections at Different Timepoints

Phase: N/A Priority: Normal
NCT ID: NCT06616571 Org: User:
Start: 09/19/24 End: 12/30/25 Due: 12/30/26

A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD)

Phase: N/A Priority: Normal
NCT ID: NCT05345236 Org: User:
Start: 08/19/19 End: 01/25/22 Due: 01/25/23

A Study Evaluates the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor Patients

Phase: N/A Priority: Normal
NCT ID: NCT03389815 Org: User:
Start: 09/14/17 End: 12/31/20 Due: 12/31/21

Trial of QLH12016 in Patients With Metastatic Castration Resistant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05973149 Org: User:
Start: 08/31/23 End: 01/01/26 Due: 01/01/27

A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC)

Phase: N/A Priority: Normal
NCT ID: NCT05262413 Org: User:
Start: 02/28/22 End: 07/30/24 Due: 07/30/25

Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05309629 Org: User:
Start: 04/18/22 End: 12/13/24 Due: 12/13/25

An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Tenofovir in Naive Patients With Chronic Hepatitis b

Phase: N/A Priority: Normal
NCT ID: NCT04157699 Org: User:
Start: 07/26/19 End: 10/31/22 Due: 10/31/23

A Multicenter, Randomized, Double-blind Phase II Trial to Evaluate GM1 Prevention of Peripheral Neuropathy in Patients With Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05802342 Org: User:
Start: 04/20/23 End: 12/31/25 Due: 12/31/26

Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Prolia® in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT04213105 Org: User:
Start: 10/31/19 End: 10/31/20 Due: 10/31/21

A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05976568 Org: User:
Start: 09/01/23 End: 09/01/27 Due: 09/01/28

Study to Investigate the Efficacy and Safety of WX-0593 in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Phase: N/A Priority: Normal
NCT ID: NCT05801107 Org: User:
Start: 10/25/21 End: 12/15/23 Due: 12/15/24

QLF32004 Injection for the Treatment of Patients With Advanced Malignant Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05108779 Org: User:
Start: 11/09/21 End: 12/30/24 Due: 12/30/25

Safety, Tolerability and Pharmacokinetics Study of QLH11906 in Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations.

Phase: N/A Priority: Normal
NCT ID: NCT05488821 Org: User:
Start: 06/14/22 End: 07/01/25 Due: 07/01/26